# CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

> **NCT00044018** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 102 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CDC-501

## Key facts

- **NCT ID:** NCT00044018
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04-01
- **Primary completion:** 2004-12-01
- **Final completion:** 2007-02-15
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044018, "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00044018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*